X

Trial Profile

Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipiracil/trifluridine (Primary)
Indications Gastric cancer
Focus Therapeutic Use

Most Recent Events

11 Oct 2016 Final results of safety, efficacy and pharmacokinetic analysis (n=29) presented at the 41st European Society for Medical Oncology Congress.
19 May 2016 Primary endpoint has been met. (Disease control rate), as per an article published in the European Journal of Cancer.
19 May 2016 Results published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com